CSL Limited this morning
announced a new agreement with
Janssen Biotech to progress the
development of a novel therapy
for haematological cancers and
autoimmune diseases.
Under the pact, Janssen has
been granted an exclusive
worldwide license to develop and
commercialise CSL362, a novel
monoclonal antibody therapy which
is currently being studied in a Phase
I clinical trial in acute myeloid
leukaemia patients who achieved
remission after chemotherapy and
are at high risk of relapse.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 13
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.